PDCD1 and aggressive NK-cell leukemia: Thus, the initiation of anti-PD-1 antibody treatment in ANKL should be cautious with preexisting HLH and “cooling” with etoposide-based chemotherapy was the key to avoid disastrous HLH flares which could be manifested as a sudden worsening of HLH-related symptoms.